Articles On Invion (ASX:IVX)

‘More of the same’ since lunchtime saw the benchmark land at -0.25% for the day Health Care coughed up a 1.09% lift while Financials weighed heavily on -0.71% Magnum Mining wins the Small Caps trophy with +44.1% thanks to Mitsubishi deal...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX climbed as high as +1.3%, easing slightly to close up 0.9%. XEC Emerging Companies and Goldies duke it out to see who can close flattest. Investors are set to pocket $35 billion in dividends between now and EOFY.   Do Not Adjust Your...

Highlights Invion has released its H1FY23 report, highlighting progress with respect to its Photosoft™ technology and lead drug candidate INV043. Photosoft™ has demonstrated positive results against antibiotic resistant MRSA bacteria,...

Highlights In a recent report and accompanying blog, CSIRO has talked about the threat that superbugs pose to humans Antimicrobial resistance is being fuelled by factors like climate change, which let superbugs to thrive in warm temper...

Highlights Photodynamic therapy (PDT) is designed to treat cancer patients using drugs activated by light. Invion Limited (ASX:IVX) is undertaking R&D of next-gen PDT as a treatment for cancer and infectious diseases. Invion’s lea...

INOVIQ announced positive results on SUBB2M Invion expands to international markets INOVIQ (ASX:IIQ) rose 5% this morning after announcing positive results for its SUBB2M breast cancer test. The company said its SubB2M-CA15.3 breast cance...

Highlights Invion and RMW Cho Group have executed a conditional agreement for the expansion of existing arrangements to co-develop Photosoft™ technology relating infectious diseases (ID indications). As per the agreement, Invion will g...

The ASX is set to rise today after a seesaw session on Wall Street Fed Chairman Jerome Powell spoke to David Rubenstein Medibank Private was hit by a class action lawsuit The ASX is set to open higher after some wild swings in New York. A...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Highlights Invion has tabled its December 2022 quarter, highlighting promising research outcomes with PhotosoftTM technology against infectious diseases. In vitro study outcomes indicated PhotosoftTM compounds’ activity against multipl...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Highlights Invion witnessed successful research outcomes in 2022, laying the groundwork for an exciting 2023 The combination therapy of the company’s lead candidate INV043 with ICI therapy resulted in a nearly 65% reduction in tumour s...

Highlights The world needs to focus on developing innovative treatments to be prepared for the next pandemic Invion’s research on PhotosoftTM compounds has demonstrated effectiveness against dengue, the Zika virus and COVID-19 variants...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Highlights Invion is going strong with research work focused on cancer and infectious diseases. The lead drug candidate INV043 has demonstrated promising results in studies covering triple negative breast cancer and anal cancers. INV0...

Highlights Invion reports that the results of its latest study indicate promise for the PhotosoftTM technology across COVID-19 variants. In the study, 9 of the 10 PhotosoftTM compounds tested displayed antiviral activity against both D...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Benchmark set to end the day down 1.5% Small caps smashed down 4.2% Greenwing up 70% on Chinese investment   Look. No-one likes Monday’s except possibly the last four or five Prime Ministers. I definitely sense S Morrison and K Rudd and c...

Highlights Invion is riding high on latest study outcomes indicating the effectiveness of its lead drug candidate INV043 in a clinically important class of tumour. In an in vitro set up, INV043 proved effective against cell lines relat...

Invion’s lead drug is found to be effective against anal cancer Althea launches new cannabis products Invion (ASX:IVX) surged 17% this morning after telling the market that its lead drug INV043 is effective against anal cancer. A vitro st...

Invion (IVX) claims the first set of results from in-vitro lab tests of its INV043 product confirm the drug’s potential to treat the full range of anal cancersThe tests, completed at the Peter MacCallum Cancer Centre in Melbourne, show the...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Highlights Invion has secured positive screening results from the in vitro study of PhotosoftTM technology against the Zika virus. Currently, there is no treatment available for the Zika virus, and its market is estimated to be worth $...

Invion’s (IVX) Photosoft compound demonstrates more than 99 per cent inhibition against the Zika virus when exposed to specific light wavelengthsThe results come from in vitro studies that were carried out by leading contract research and c...

There’s a new development in the fight against the Zika virus. Invion (ASX:IVX) has just demonstrated that its Photosoft compounds were >99% effective in cell-based assays following the application of light. The study showed that Photoso...

Aussie markets are flat, flat, flat (actually the benchmark found 0.1%) Banks are lower, consumer names higher Explorers Devex and Tempus have found big things in the ground   There’s about 15 minutes of trade on the ASX and I’m calling b...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

The ASX 200 ends ever so slightly up, XEC finds 0.4% Gains in consumer discretionary, tech offset big losses for energy, resources, materials. South Korea, Kiwi’s lift rates ahead of tonight’s US CPI read Investors are facing crunch time...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

HitIQ and Volpara sign major deals in the US ECS Botanics makes first cannabis flower shipment to NZ Invex to commence Phase III study in Australia Following its extension contract with New Zealand Rugby a couple of weeks ago, HitIQ (ASX:...

The ASX is set to open more than 1% lower today as Wall Street plunges overnight Tech stocks led the selloff in the US Bitcoin is set to be regulated as a commodity by the US SEC The ASX is poised to open more than 1% lower this morning,...

Invion (IVX) confirms combination therapy of INV043 and immune checkpoint inhibitors (ICI) is more effective than just ICI therapy in its latest proof-of-concept (PoC) study The findings are from Invion’s third PoC study undertaken by its...

Invion demonstrates high efficacy of INV043 when used as a combined therapy Biotron gets positive feedback from US FDA Biome stocks its Probiotics range on Priceline’s shelves Invion demonstrates efficacy Cancer fighter Invion (ASX:IVX) w...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Life sciences company Invion (ASX: IVX) is raising $15 million to continue developing the Photosoft technology and expand its addressable markets for treating cancer and related diseases using the next generation technology. Invion has exec...

Invion (IVX) is aiming to raise $15 million in additional capital to help fund the expansion of its Photosoft technology co-development deal IVX and RMW Cho Group will co-develop the tumour regression treatment technology for use on cance...